LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

Baxter International Inc

Gesloten

SectorGezondheidszorg

20.73 0.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.15

Max

20.92

Belangrijke statistieken

By Trading Economics

Inkomsten

-984M

-1B

Verkoop

139M

3B

K/W

Sectorgemiddelde

86.308

108.767

EPS

0.44

Dividendrendement

2.41

Winstmarge

-34.802

Werknemers

37,500

EBITDA

-59M

357M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-3.05% downside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.41%

2.21%

Volgende Winsten

30 apr 2026

Volgende dividenddatum

1 apr 2026

Volgende Ex Dividend datum

27 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-232M

11B

Vorige openingsprijs

20.25

Vorige sluitingsprijs

20.73

Nieuwssentiment

By Acuity

17%

83%

27 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Baxter International Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 feb 2026, 20:10 UTC

Winsten

Baxter Is One of the S&P 500's Worst Performers Today. Earnings Were Brutal. -- Barrons.com

12 feb 2026, 14:43 UTC

Winsten

Baxter Is One of the S&P 500's Worst Performers Today. Earnings Were Brutal. -- Barrons.com

Peer Vergelijking

Prijswijziging

Baxter International Inc Prognose

Koersdoel

By TipRanks

-3.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 20 USD  -3.05%

Hoogste 25 USD

Laagste 15 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Baxter International Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

12 ratings

2

Buy

9

Hold

1

Sell

Technische score

By Trading Central

30.475 / 31.345Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

27 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat